Stay updated with breaking news from Confidence Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 -- HUTCHMED Limited ; class='js-l-obf link link--blue'
An analysis of data from more than 60,000 women details associations between specific chronotypes and risk of unhealthy lifestyle behaviors as well as risk of developing type 2 diabetes.
1. In this phase three open-label randomized trial, concizumab prophylaxis reduced the annualized bleeding rate in patients with hemophilia with inhibitors as compared to placebo control. 2. While overall and serious adverse events were not significantly different between control and concizumab groups, the trial was temporarily suspended due to nonfatal thromboembolic events in three patients
1. In this randomized controlled trial, among patients living with human immunodeficiency virus (HIV) at low-to-moderate risk of cardiovascular disease, pitavastatin calcium was superior to placebo in reducing the risk of a major adverse cardiovascular event (MACE). 2. The trial was stopped early due to evidence of the efficacy and safety of pitavastatin. Evidence Rating
Data from longest reported follow-up for a Phase 3 trial with immunotherapy in metastatic non-small cell lung cancer demonstrate consistent, durable benefits of Opdivo plus Yervoy vs. chemotherapy at...